Newsmeme!
Discover News you didn't know existed
Tysabri
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Dow component sees unusual options activity
Published July 9, 2009, 11:51 am, Schaeffers Research
Option activity is brisk on Dow Jones Industrial Average (DJIA) component General Electric Company (GE: sentiment, chart, options) today...( Read More )
Biogen wins speedy FDA review for MS drug
Published July 8, 2009, 11:28 am, Mass High Tech: The Journal of New England Technology
The U.S. Food and Drug Administration has granted “Fast-Track” status for a Biogen drug target for multiple sclerosis. Biogen is currently enrolling patients in a Phase 3 clinical trial for the drug, called PEGylated interferon beta-1a (BIIB017).
Biogen-Idec MS drug put on FDA Fast Track
Published July 8, 2009, 10:25 am, BizJournals
A multiple sclerosis drug being developed by Biogen Idec has won Fast Track designation from the U.S. Food and Drug Administration – opening the door for a quicker trip through the approval process.
Biogen wins fast-track clearance from FDA
Published July 8, 2009, 8:19 am, BizJournals
The U.S. Food and Drug Administration has granted Fast Track status for a Biogen Idec Inc. drug target for Multiple Sclerosis.
New Report Just Published: Global Cancer Therapies
Published July 7, 2009, 3:20 am, Business Wire via Yahoo! Finance
NEW YORK----Reportlinker.com just added a new market research report to its catalogue.
Oil and gas production company attracts heavy put volume
Published July 6, 2009, 11:51 am, Schaeffers Research
Analysts at Caris cut their price target on oil and gas producer Frontier Oil Corp...( Read More )
A Fool Looks Back
Published July 5, 2009, 7:23 am, The Motley Fool
Fraudsters, failings, and fortunes sat still long enough for their portraits this week.
Mri Data Showing Tysabri® Promoted Remyelination Presented At The 61st Annual Meeting Of The American Academy Of ...
Published July 4, 2009, 4:10 am, Medical News Today
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced results of a study demonstrating that TYSABRI® (natalizumab) promoted regeneration and stabilization of damage done to the myelin sheath, as measured by advanced MRI technology. Damage to the myelin sheath causes the symptoms of multiple sclerosis (MS).
Biogen Reports No New PML Cases In Weekly Tysabri Update
Published July 3, 2009, 3:07 pm, Nasdaq
NEW YORK -(Dow Jones)- Biogen Idec Inc. (BIIB) reported no new cases of a rare brain infection in users of the multiple sclerosis drug Tysabri in the company's weekly update Friday.
Johnson & Johnson pays $1B for Elan stake
Published July 3, 2009, 7:45 am, Daily Record
Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's disease, is taking a major stake in Irish biopharmaceutical company Elan Corp., investing up to $1.5 billion initially.
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |